B1 Cncld.

analogues used in the inventive method. Such super-promiscuous epitopes will allow for the most simple embodiments of the invention wherein only one single modified amyloidogenic polypeptide is presented to the vaccinated animal's immune system.

Please replace the paragraph beginning on page 58, line 6 with the following amended paragraph:

B2

It should be noted that preferred modified amyloidogenic molecules comprises modifications which results in a polypeptide having a sequence identity of at least 70% with an amyloidogenic protein or with a subsequence thereof of at least 10 amino acids in length. Higher sequence identities are preferred, e.g. at least 75% or even at least 80, 85, 90 or 95%. The sequence identity for proteins and nucleic acids can be calculated as $(N_{ref} - N_{dif}) \cdot 100/N_{ref}$, wherein N_{dif} is the total number of non-identical residues in the two sequences when aligned and N_{ref} is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC (SEQ ID NO:17) will have a sequence identity of 75% with the sequence AATCAATC (SEQ ID NO:18) (N_{dif}=2 and N_{ref}=8).

Please replace the Sequence Listing filed February 20, 2001 located immediately after the claims with the substitute Sequence Listing enclosed herewith.